Posted by Michael Wonder on 24 May 2018
Sandoz receives European Commission approval for Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases
24 May 2018 - Zessly is the third EC approval for a Sandoz biosimilar in 12 months.
Sandoz, a Novartis division and the global leader in biosimilars, today announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.
Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn's disease, paediatric Crohn's disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
